We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
4d Molecular Therapeutics Inc
6 own
5 watching
Current Price
$7.24
$0.06
(0.84%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
797.73M
52-Week High
36.25000
52-Week Low
6.77000
Average Volume
0.84M
Dividend Yield
--
P/E Ratio
--
Market Capitalization797.73M52-Week High36.2500052-Week Low6.77000Average Volume0.84MDividend Yield--P/E Ratio--What does the 4d Molecular Therapeutics Inc do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Read More
How much money does 4d Molecular Therapeutics Inc make?
News & Events about 4d Molecular Therapeutics Inc.
Globe Newswire
1 year ago
EMERYVILLE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today that it priced an upsized underwritten ...
Zolmax
1 year ago
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT Get Rating) insider Scott Bizily sold 3,750 shares of the companys stock in a transaction that occurred on Friday, April 21st. The stock was sold at an average price of $20.00, for a total value of $75,000.00. Following the transaction, the...
Ticker Report
1 year ago
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT Get Rating) insider Scott Bizily sold 3,750 shares of the companys stock in a transaction that occurred on Friday, April 21st. The stock was sold at an average price of $20.00, for a total value of $75,000.00. Following the transaction, the...
Zolmax
1 year ago
4D Molecular Therapeutics (NASDAQ:FDMT Get Rating)s stock had its buy rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $36.00 target price on the stock. HC Wainwrights price objective would indicate a ...
Globe Newswire
1 year ago
Expands Large Market Ophthalmology Portfolio Following Positive Clinical Data in wet Age-Related Macular Degeneration to Include Diabetic Macular Edema Clinical Program and Geographic Atrophy Preclinical ProgramExpands Large Market Pulmonology Portfolio Following Positive Clinical Data in Cystic ...
Frequently Asked Questions
Frequently Asked Questions
What is 4d Molecular Therapeutics Inc share price today?
Can Indians buy 4d Molecular Therapeutics Inc shares?
How can I buy 4d Molecular Therapeutics Inc shares from India?
Can Fractional shares of 4d Molecular Therapeutics Inc be purchased?
What are the documents required to start investing in 4d Molecular Therapeutics Inc stocks?
What is today’s traded volume of 4d Molecular Therapeutics Inc?
What is today’s market capitalisation of 4d Molecular Therapeutics Inc?
What is the 52-Week High and Low Range of 4d Molecular Therapeutics Inc?
What percentage is 4d Molecular Therapeutics Inc down from its 52-Week High?
What percentage is 4d Molecular Therapeutics Inc up from its 52-Week Low?
Current Price
$7.24
$0.06
(0.84%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.